Prevalence of the Triple-Negative Phenotype in Mexican Patients with Breast Cancer Treated in Private Practice
Ana Olivia Cortes-Flores1, Gilberto Morgan-Villela1, Jorge Jiménez-Tornero1, Carlos Zuloaga-Fernández del Valle1, Guillermo Juárez- López1, Clotilde Fuentes-Orozco2, Michel Dassaejv Macías-Amezcua2, Rodrigo Ville-Benavides1, Ernesto Alejandro Juárez-Uzeta1 and Alejandro González-Ojeda2*
- *Corresponding Author:
- Alejandro González-Ojeda
Research Unit in Clinical Epidemiology
Western Medical Center, Avenida Belisario Domínguez 1000
Colonia Independencia, CP 44340
Guadalajara, Jalisco, Monaco
E-mail: [email protected]
Received date: May 12, 2014; Accepted date: June 27, 2014; Published date: July 02, 2014
Citation: Cortes-Flores AO, Morgan-Villela G, Jiménez-Tornero J, del Valle CZF, Juárez-López G, et al. (2014) Prevalence of the Triple-Negative Phenotype in Mexican Patients with Breast Cancer Treated in Private Practice. J Women’s Health Care 3:170. doi:10.4172/2167-0420.1000170
Copyright: © 2014 Cortes-Flores AO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Identifying the biological profile of breast cancer is fundamental to predict the response to various treatments and for prognosis. The aim of this study was to determine the triple-negative breast cancer prevalence in patients treated in private practice in Mexico.
Methods: The study was performed using Mexican patients older than 18 years and had a histopathological diagnosis of breast adenocarcinoma and immunohistochemical studies for estrogen, progesterone, and HER2/Neu receptors, according to validated standards.
Results: A total of 1,989 patients with a mean age of 52.9 ± 13.4 (23–93) years and a tumor size of 2.72 ± 1.12 cm were evaluated. The TNBC biological subtype was observed in 17.3%, HER2/Neu overexpression in 22.6%, and the presence of positive hormonal receptors (estrogen and/or progesterone) in 60.1% of the cases. An association was found between the TNBC type and the degree of differentiation (P<0.01), p53 overexpression (P<0.01, OR=1.84, 95% CI 1.35–2.52), proliferation index (P<0.01, OR=1.83, 95% CI 1.44–2.34), and tumor size (P<0.01). TNBC patients were younger (P<0.01) and lymph node involvement was more common in these patients (P<0.01, OR=4.57, 95% CI 3.53–5.90).
Conclusions: TNBC is a highly aggressive tumor with a lower prevalence in women treated in private practice than in patients treated through the Seguro Popular, probably as a consequence of faster detection and opportune treatment.